Cantor Fitzgerald Reiterates Overweight Rating for Krystal Biotech (NASDAQ:KRYS)

Cantor Fitzgerald restated their overweight rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note released on Thursday morning,Benzinga reports. They currently have a $215.00 target price on the stock.

Several other equities analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday. Citigroup upped their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Chardan Capital lifted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Krystal Biotech currently has an average rating of “Buy” and a consensus target price of $210.00.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $187.86 on Thursday. The company has a market capitalization of $5.41 billion, a price-to-earnings ratio of 62.83 and a beta of 0.84. The business has a 50 day moving average of $157.85 and a 200 day moving average of $175.28. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million for the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company’s revenue for the quarter was up 116.4% compared to the same quarter last year. During the same period last year, the firm earned $0.30 earnings per share. As a group, sell-side analysts anticipate that Krystal Biotech will post 6.14 EPS for the current year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 14.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

Several hedge funds and other institutional investors have recently made changes to their positions in KRYS. GF Fund Management CO. LTD. purchased a new stake in Krystal Biotech during the 4th quarter valued at about $95,000. Palisades Investment Partners LLC lifted its stake in Krystal Biotech by 9.3% during the 4th quarter. Palisades Investment Partners LLC now owns 40,479 shares of the company’s stock valued at $6,341,000 after acquiring an additional 3,436 shares during the period. Woodline Partners LP boosted its holdings in shares of Krystal Biotech by 23.0% during the 4th quarter. Woodline Partners LP now owns 221,102 shares of the company’s stock valued at $34,638,000 after acquiring an additional 41,287 shares during the last quarter. Soleus Capital Management L.P. boosted its holdings in shares of Krystal Biotech by 65.2% during the 4th quarter. Soleus Capital Management L.P. now owns 358,379 shares of the company’s stock valued at $56,144,000 after acquiring an additional 141,400 shares during the last quarter. Finally, ProShare Advisors LLC grew its stake in shares of Krystal Biotech by 28.6% in the fourth quarter. ProShare Advisors LLC now owns 8,848 shares of the company’s stock worth $1,386,000 after acquiring an additional 1,967 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).